Conectar con nosotros

EU

Lehendakaritzako hitzaldi medikuntza pertsonalizatua 'stock hartzen'

PARTEKATU:

Argitaratutako

on

Zure erregistroa baimendutako moduetan edukia eskaintzeko eta zure ezagutza hobetzeko erabiltzen dugu. Harpidetza edozein unetan har dezakezu.

March13_2013_20712441_DrDrawingMolecule_PersonalizedMedBioP2718276218By Europako Aliantza pertsonalizatua Medikuntza (EAPM) Zuzendari Exekutiboa Denis Horgan 

A landmark conference takes place in Luxembourg today (9 July) on personalised medicine, which is one of the thematic focuses of the new rotating presidency of the European Union.

The results of the high-level meeting, entitled ‘Making Access to Personalised Medicine a Reality for Patients’, will eventually feed in to Luxembourg’s Council Conclusions in December this year.

iragarki

The conference, in Luxembourg City, aimed to assess and address obstacles to the integration of personalised medicine into Europe’s healthcare systems, identify best practices and the added value that such an approach can deliver, and outline the potential benefits that a personalised medicine approach could have on public health and its impact on policymaking in the EU.

Luxembourg’s health minister, Lydia Mutsch, told delegates: “The Luxembourg Presidency has made personalised medicine one of its health policy priorities. By taking stock of where we are in Europe in terms of access to personalised medicine, (we hope to) highlight opportunities to accelerate progress.”  She added that, through the conference, the scene for further action can be set and that the most important focus of the discussions was on the public health dimension of personalised medicine and particularly on the patient.

Brussels-based EAPM (the European Alliance for Personalised Medicine) was instrumental in putting personalised medicine on the political map and the Luxembourg minister’s comments reflected the Alliance’s ‘SMART’ agenda, which stands for Smaller Member States And Regions Together. The idea of ‘taking stock’ also dovetails with the over-arching theme of EAPM’s 4th annual presidency conference, scheduled for Spring 2016 during the presidency of the Netherlands.

iragarki

The health minister recently said: “The exciting field of personalised medicine is, and should be, all about the patients. It offers the opportunity for them to be seen not merely as passive recipients of care but as participants, partners and even guides in their own healthcare.”  The conference heard that, with an ageing population of 500 million across 28 member states, Europe needs to take urgent action in the area of health. While consensus is not always possible, there needs to be a coalition of the willing.  Mary Baker, of the European Brain Council and an EAPM Board Member, spoke about the role of EAPM in bringing stakeholders together and the need for collaboration.

She added: “There’s some great science out there, but we need to build a motorway between the various disciplines – and include patients – to help speed a process that currently takes a medicine around 13-and-a-half years to get from bench to bedside.”  Helmut Brand, EAPM Co-Chair, reiterated the point that multistakeholder collaboration was vital to moving personalised medicine forward, adding that EAPM had been doing this successfully since its formation.

Brand also said that: “Europe needs formats and philosophies that allow flexibility throughout the whole family of 28 Member States, ones in which different regions within countries can collaborate, and countries can collaborate.  “The EU needs to provide a framework that can facilitate this,” Brand added, “to allow us to go beyond words and aspirations and dreams, to allow us to provide real outcomes in order that citizens, businesses, health-care workers and patients do not get frustrated.”

Denis Lacombe, from EORTC, spoke about the work of the EAPM Consensus Group on Clinical Trials and told the conference: “Traditionally, the randomized clinical trial has been the bedrock upon which practice-changing clinical advances in medicine have been founded. However, the classical approach is not the most optimal in the era of personalised medicine. Clinical trials must address, in a comprehensive and transparent fashion, the needs of all stakeholders. We need to set the efficacy bars much higher than they are currently at the start of the process.”

Christine Chomienne, head of the European Haematology Association, spoke about EAPM’s plans for an Education Summer School in 2016 to fill the gap between the advances in treatments and the knowledge of front-line clinicians.  She said: “Health-care professionals cannot be expected to adapt to new ways of approaching patients and coping with new technology unless they are suitably trained.  “Professionals prescribing, dispensing and administering medicines will need to be confident of the science behind targeted therapies and communication skills with patients will also need to be developed.

Chomienne added: “Employers, professional organisations, certification entities, regulatory agencies, and others will have to be involved in effecting the necessary changes.”  John Bowis, a former UK health minister and the chairman of the session on ‘The value of PM for Public Health, its impact on EU Health Policy’, spoke about cross-border health issues.

He said: “In 1998, health policy was moved on, not by the Commission or Council or Parliament but by the European Court of Justice. I was appointed by the European Parliament to be rapporteur for Cross-Border Healthcare.

"The right to cross-border health care is now enshrined in European law. But it is not perfect and we will have to work to ensure that patients have these rights. Now, citizens have the right to travel to another part of the European Union to receive medical treatment and, so long as the treatment was normally available in the home country and the reimbursable cost was no more than would have been paid in the home country, then the patient should be reimbursed.”

Angela Brand from Maastricht University spoke about a clear need for a European Translational Research Platform (ETRP).  She said: “Through focused presidencies, EAPM and the stakeholders in this room and beyond, we need to create an ETRP to enable the efficient translation of research discoveries to innovative diagnostics, therapeutics, products and processes that will benefit European patients, industries and societies.  The ETRP should, she added, link infrastructure in relevant domains including ‘omics, pathology, biorepositories and biobanks, share the expertise across the translational research continuum, and enable active cooperation between all relevant stakeholders to remove structural, regulatory, and other barriers.

“Clearly crucial to the success of ETRP is the designation of specific funding mechanisms at national and European level to drive the effective translation of European scientific excellence,” she said.  Brand also said that there should be: “Research at the convergence of mHealth, Big Data, Cloud Computing, plus security and anonymisation techniques to meet the requirements of High Performance Computing and data throughput throughout the life sciences and healthcare value chains.”  She also highlighted “new models of data ownership”, such as the idea of Data Co-operatives in which patients own the data, can decide when and where it can be used and can choose into which areas of research any reimbursements should go.

On that theme, Kaisa Immonen-Charalambous (European Patient Forum) pointed out that patients are willing to share their data for health purposes as long as the correct safeguards are in place. In this way, of course, new treatments can be developed.  And Executive Director of the Alliance Denis Horgan said: “Patients today are more aware of the clinical improvements that can be achieved through the use of personalised-medicine tools such as biomarker tests. Patients need empowerment, which means good access to information, and an ability to participate fully in discussions about the management of their disease.”

On a more specific note, he pointed out that member states may need support in developing their national cancer care plans to incorporate biomarker testing as an essential and standard part of best clinical practice.   Meanwhile, he added: “Regulations often lag behind the science and, in this way, are not fit-for-purpose. This is because the regulations did not foresee what will become an explosion in, for example, personalised medicine-based clinical trials.

“We cannot pre-solve every problem as we don’t yet know them all. The very best we can do is put in place a framework that allows real actions – albeit ones that follow, underline and match our values through sets of guidelines and codes of ethics.”

guidelines and codes of ethics."

Cyprus

NextGenerationEU: Europako Batzordeak 157 milioi euro ordaindu dizkio aurrez finantzatutako Zipri

Argitaratutako

on

Europako Batzordeak 157 milioi euro eman dizkio Zipri aurrefinantzaketan, berreskurapen eta erresilientzia tresnaren (RRF) herrialdeko finantza-zuzkiduraren% 13ren baliokidea. Aurrez finantzatutako ordainketak Zipreko berreskurapen eta erresilientzia planean zehaztutako inbertsio eta erreforma neurri erabakigarriak ezartzen lagunduko du. Batzordeak Zipreko berreskurapen eta erresilientzia planean zehaztutako inbertsioak eta erreformak gauzatzean oinarritutako beste ordainketa baimenduko du.

Herrialdeak 1.2 mila milioi euro jasoko ditu guztira bere planean zehar, 1 mila milioi euro laguntzetan eta 200 milioi euro maileguetan emango dira. Gaurko ordainketa NextGenerationEUren lehen mailegu-eragiketak azkenaldian arrakastaz gauzatu ondoren. Urte amaierarako, Batzordearen asmoa da guztira 80 milioi euro biltzea epe luzeko finantzaketan, epe laburreko EBko fakturekin osatzeko, NextGenerationEUren arabera estatu kideei aurreikusitako lehen ordainketak finantzatzeko. NextGenerationEUren zati denez, RRFk 723.8 milioi euro emango ditu (egungo prezioetan), estatu kideetako inbertsioak eta erreformak laguntzeko.

Zipreko plana COVID-19 krisitik indartsuago ateratzeko aurrekaririk gabeko EBren erantzunaren parte da, trantsizio berdeak eta digitalak sustatuz eta gure gizarteetako sendotasuna eta kohesioa indartuz. A Prentsa-oharra eskuragarri online da.

iragarki

Jarraitu irakurtzen

Belgikan

EBko Kohesio politika: Belgikak, Alemaniak, Espainiak eta Italiak 373 milioi euro jaso dituzte osasun eta gizarte zerbitzuei, ETEei eta gizarteratzeari laguntzeko

Argitaratutako

on

Batzordeak 373 milioi euro eman dizkie bostei Europako Gizarte Funtsak (ESF) eta Eskualde Garapeneko Europako Funtsak (EGEF) programa operatiboak (OP) Belgikan, Alemanian, Espainian eta Italian, koronabirusaren larrialdiei erantzuteko eta konpontzeko arazoak dituzten herrialdeei laguntzeko REACT-EB. Belgikan, Valoniako OP aldaketak 64.8 milioi euro gehiago jarriko ditu eskuragarri osasun zerbitzuetarako eta berrikuntzarako ekipamendu medikoa eskuratzeko.

Funtsak enpresa txiki eta ertainei (ETEei) lagunduko die merkataritza elektronikoa, zibersegurtasuna, webguneak eta lineako dendak garatzen, baita eskualdeko ekonomia berdea ere energia-eraginkortasunaren, ingurumenaren babesaren, hiri adimendunen garapenaren eta karbono gutxiko garapenaren bidez. azpiegitura publikoak. Alemanian, Hessen Estatu Federalean, 55.4 milioi euro lagunduko ditu osasunarekin lotutako ikerketa azpiegiturak, diagnostiko gaitasuna eta berrikuntza unibertsitateetan eta beste ikerketa erakunde batzuetan, baita klima eta garapen iraunkorraren alorreko ikerketa, garapen eta berrikuntza inbertsioak ere. Aldaketa honen bidez, laguntza emango zaie ETEei eta inbertsio funts baten bidez hasiberrientzako funtsak.

Sachsen-Anhalt-en, 75.7 milioi euro ETEek eta erakundeek lankidetza erraztuko dute ikerketan, garapenean eta berrikuntzan, eta inbertsioak eta kapital aktiboa eskaintzea koronabirusaren krisiak eragindako mikroenpresei. Gainera, funtsak enpresen energia eraginkortasunean inbertsioak egitea ahalbidetuko dute, ETEen berrikuntza digitala lagunduko dute eta ikastetxe eta kultur erakundeentzako ekipamendu digitala eskuratuko dute. Italian, "Gizarteratzea" PO nazionalak 90 milioi euro jasoko ditu gabezia material larria, etxegabetzeak edo muturreko marjinazioa jasaten duten pertsonen gizarteratzea sustatzeko, berehalako etxebizitza eskaintzea eta gizarte eta enplegu zerbitzuak ahalbidetzen dituzten "Housing First" zerbitzuen bidez. .

iragarki

Espainian, 87 milioi euro gehituko zaizkio Gaztela eta Leongo FSE POari, krisiaren ondorioz kontratuak eten edo murriztu zituzten autonomoei eta langileei laguntzeko. Diruari esker, kalte handiko enpresek kaleratzeak saihesten lagunduko dute, batez ere turismoaren sektorean. Azkenean, funtsezkoak dira funtsezko gizarte zerbitzuek modu seguru batean jarrai dezaten eta pandemia osoan hezkuntza jarraitasuna bermatzeko langile osagarriak kontratatuz.

REACT-EU-ren parte da NextGenerationEU eta 50.6 mila milioi euroko finantzazio gehigarria eskaintzen du (egungo prezioetan) Kohesio politikako programetarako 2021 eta 2022. urteetan zehar. Neurriak lan merkatuko erresilientziari, lanpostuei, ETEei eta diru sarrera baxuetako familiei laguntzeaz gain, etorkizuneko oinarriak finkatzea da. trantsizio berdeak eta digitalak eta suspertze sozioekonomiko iraunkorra.

iragarki

Jarraitu irakurtzen

Europako Batzordeak

NextGenerationEU: Europako Batzordeak 2.25 mila milioi euro aurrez finantzatu dizkio Alemaniari

Argitaratutako

on

Europako Batzordeak 2.25 mila milioi euro eman dizkio Alemaniari aurrefinantzaketan, berreskuratzeko eta Errezilotzeko Instalazioaren (RRF) herrialdeko finantza-zuzkiduraren% 9ren baliokidea. Hau Alemaniak berreskuratzeko eta erresilientzia planean eskatutako aurrez finantzatutako zenbatekoari dagokio. Aurrez finantzatutako ordainketak Alemaniaren suspertze eta erresilientzia planean zehaztutako inbertsio eta erreforma neurri erabakigarriak ezartzen lagunduko du. Batzordeak Alemaniako berreskurapen eta erresilientzia planean zehaztutako inbertsioak eta erreformak gauzatzean oinarritutako beste ordainketa baimenduko du.

Herrialdeak 25.6 milioi euro jasoko ditu guztira, dirulaguntzez osatuta, bere planean zehar. Ordainketa NextGenerationEUren lehen mailegu-eragiketak azkenaldian arrakastaz gauzatu ondoren. Urte amaierarako, Batzordearen asmoa da guztira 80 milioi euro biltzea epe luzeko finantzaketan, epe laburreko EBko fakturekin osatzeko, NextGenerationEUren arabera estatu kideei aurreikusitako lehen ordainketak finantzatzeko. NextGenerationEU-ren zati bat, RRF-k 723.8 milioi euro emango ditu (egungo prezioetan) estatu kideetako inbertsioak eta erreformak laguntzeko. Alemaniako plana COVID-19 krisitik indartsuago ateratzeko aurrekaririk gabeko EBren erantzunaren parte da, trantsizio berdeak eta digitalak sustatuz eta gure gizarteetako sendotasuna eta kohesioa indartuz. Prentsa ohar osoa dago eskuragarri hemen.

iragarki

Jarraitu irakurtzen
iragarki
iragarki
iragarki

Modako